In this QCast episode, co-hosts Jullia and Tom discuss clinical study start up and the practical work that takes a trial from planning into execution. The conversation looks at what this phase really involves, including feasibility, budgeting, contracts, ethics and regulatory submissions, and site readiness, and why it matters so much in day-to-day delivery. When study start up is handled well, sites can open on a more reliable basis and teams are less likely to carry avoidable disruption into enrolment.
The episode also focuses on where start up pressure tends to build. Jullia and Tom look at common misconceptions, including the idea that delays are mainly caused by regulatory review, and spend time on the less visible problems that often slow studies down, such as handoffs, waiting time, unclear ownership, and poorly coordinated parallel activity. They also explain why measurement matters, because without a clear view of cycle time, approval duration, and internal delays, teams can struggle to tell the difference between unavoidable elapsed time and problems they could actually fix.
What Clinical Study Start Up Actually Covers
Clinical study start up is the phase where a trial moves from planning into execution. It includes feasibility, budgeting, contracts, ethics and regulatory submissions, and the work needed to make sure sites are genuinely ready to open and enrol participants. Because these activities sit so close to first patient enrolment, weaknesses here can affect timelines and study conduct very quickly.
Why Delays Often Build Outside Formal Review Timelines
Study start up delays do not come only from ethics or regulatory review. Budget development, contract negotiation, document handoffs, unanswered questions, and unclear ownership can all create waiting time that quietly stretches activation timelines. In many studies, those gaps between tasks are just as important to manage as the tasks themselves.
What Makes Study Start Up More Predictable in Practice
Study start up tends to work better when it is treated as a controlled operational phase rather than a loose set of pre-study activities. Feasibility needs to test real deliverability, parallel workstreams need to be managed properly, and teams need visibility into cycle time, approval duration, and internal delays. When those basics are in place, sites can activate on a more reliable basis and the study is less likely to carry avoidable disruption into enrolment.
Jullia
Welcome to QCast, the show where biometric expertise meets data-driven dialogue. I’m Jullia.
Tom
I’m Tom, and in each episode, we dive into the methodologies, case studies, regulatory shifts, and industry trends shaping modern drug development.
Jullia
Whether you’re in biotech, pharma or life sciences, we’re here to bring you practical insights straight from a leading biometrics CRO. Let’s get started.
So today we’re talking about clinical study start up. Now this is the phase where a trial moves from planning into execution. It covers the work needed to get the study ready for first patient enrolment, so things like feasibility, budgeting, contracts, ethics and regulatory submissions. Plus making sure sites are genuinely ready to open. It matters because decisions made here shape how quickly sites activate and how much disruption gets carried into the rest of the trial.
Tom
And it’s worth separating that from site start up, isn’t it? Those terms get blurred quite a lot.
Jullia
They do. So study start up is broader and sits at protocol or programme level. It creates the conditions that let sites be initiated properly, whereas site start up is the work happening at each individual site to meet those conditions. In practice, study start up is about getting to the point where sites are authorised and operationally ready to enrol.
Tom
So before anyone starts chasing dates, there’s a basic question underneath all of this, which is whether the study can actually be delivered as planned. Now is that where feasibility comes in?
Jullia
Yes, exactly. Feasibility is one of the first serious decision points in start up. It’s where teams test whether the protocol can realistically run at the proposed sites, within the expected timelines and with the resources available. That means looking at patient availability, competing studies, site experience, staffing, and the operational burden the protocol creates.
Tom
Now when you say operational burden, what does that look like in real terms?
Jullia
Well it can be very concrete. A visit schedule might look manageable on paper, but once you layer in extra lab collections, tighter windows, more adverse event review, or complex dosing checks, the burden on the site changes quite a bit. A site might be strong clinically, but if the protocol asks for a lot of coordination in a short period, that can affect whether they can recruit and run the study well.
Tom
So feasibility is more like an early test of whether the plan survives contact with reality.
Jullia
Yes, I believe that’s a good way to put it. If feasibility is treated as a formality, teams can end up discovering basic problems much later, when the cost of changing course is higher. Used properly, it gives sponsors a chance to refine site selection, challenge assumptions, or pause before avoidable delays and costs build up.
Tom
Now I think some people hear start-up and assume the main delay is regulatory review. But that’s only part of it, right?
Jullia
You’re right. Regulatory and ethics review are central, but they’re not the only pressure points. Budget development and contract negotiation are very common sources of delay, and sometimes they drag on longer than expected because ownership isn’t clear or escalation happens too late. A study can be scientifically ready, but still stuck because the financial and legal framework for site activation hasn’t been finished.
Tom
Can you give a simple example of how that kind of delay shows up?
Jullia
Yes, so a site may have given positive feasibility feedback and be keen to participate, but the site budget is still under review, the confidentiality agreement took longer than expected, or the clinical trial agreement is sitting with legal teams on both sides. None of that is unusual. The problem is when there’s no disciplined workflow for moving those items forward, because then waiting time starts to dominate the timeline.
Tom
Now that waiting time is interesting, because teams often talk about tasks taking too long, when sometimes the real issue is the gap between tasks.
Jullia
Yes, and that gap can be surprisingly costly. There’s often more time lost in handoffs, queueing, and waiting for review than in the task itself. One group finishes its part, another group doesn’t realise something is ready, a question sits unanswered for a few days, or a document comes back for changes without a clear owner. Those pauses can add up very quickly across multiple sites.
Tom
And that’s before you even get into differences between countries, site types, or approval pathways.
Jullia
Exactly, because review routes can vary a lot depending on geography and study design. Some submissions sit at sponsor level, some at site level, and sometimes both. That’s why ethics and regulatory work has to be managed as an active parallel workstream, not something that gets left until everything else is done.
Tom
So if someone says, “We’ll sort the contracts first and then move to ethics,” that sounds neat, but it could actually slow things down.
Jullia
It often does. Start-up works better when dependencies are understood properly and parallel activity is used where it makes sense. The aim isn’t to create noise or rush people. It’s to avoid a serial process where each team waits for the previous one, even when parts of the work could have moved earlier.
Tom
Now that brings us to roles, because multi-stakeholder work gets messy quite fast when nobody is sure who owns the next step. Who needs to be clear on what?
Jullia
Pretty much everyone involved. Sponsors, CROs, sites, ethics committees, and vendors all play a role in start up, and delays often come from gaps or duplication between them rather than from one dramatic failure. Project managers usually hold the coordination piece, so they track timelines, dependencies, and risks, while sites provide feasibility input, local documents, and readiness activity. Sponsors and CROs still need clear accountability for the overall delivery. Because when that accountability is vague, you get a lot of motion without much progress.
Now a team can feel busy because people are sending emails, updating trackers, and chasing documents, but if ownership is blurred, decisions still stall. One short aside here: sometimes the tracker gets blamed, but the tracker usually isn’t the problem. It’s just showing that nobody agreed who had the decision.
Tom
So what actually helps teams keep start up under control day to day?
Jullia
Standardised tools and processes help a lot, provided they’re used well. Checklists, timelines, and process maps make requirements explicit and show where handoffs, approvals, and reviews sit. They also make it easier to see what is waiting, who needs to act next, and where variation between studies or sites is creating avoidable friction.
Tom
There’s also probably a misconception here that delays are mostly external, so teams just have to live with them. Is that too simplistic?
Jullia
Yes, I think it is. Some review time is unavoidable, and some variation between sites or authorities is real. But without measurement, teams tend to attribute too much to external factors and miss what is happening inside their own process. If you’re not tracking cycle time, approval duration, and handoff delays, it’s hard to tell the difference between unavoidable elapsed time and avoidable waiting time.
Therefore, measuring start up performance lets teams move from reacting to problems to improving the process deliberately. If one study is repeatedly slowed by contract review, or if site activation stalls after ethics approval because documents sit unreviewed, that gives you something specific to fix. Without that visibility, people tend to rely on anecdote.
Tom
Before we wrap up, what should listeners take away from today’s discussion?
Jullia
Clinical study start up works better when it’s treated as a controlled phase rather than a blur of pre-study tasks. Feasibility needs to test real deliverability, not just gather optimistic signals. And the biggest gains often come from clear ownership, parallel work where appropriate, and measuring where time is genuinely being lost.
Tom
So when start up goes well, what does that usually mean for the rest of the study?
Jullia
Well usually it means fewer resets later. Sites are activated on a more reliable basis, expectations are clearer, and teams aren’t carrying as much hidden operational risk into enrolment. You still get issues, of course, but you’re not starting from a position where the trial is already compensating for preventable delays and unclear decisions.
And if we pull the whole conversation together, this really comes down to treating start up as something measurable and manageable. Be realistic early through feasibility, keep contracts and reviews moving with proper ownership, and make the waiting time visible rather than focusing only on the tasks themselves. If teams do those things well, start-up becomes much more predictable.
With that, we’ve come to the end of today’s episode on clinical study start up. If you found this discussion useful, don’t forget to subscribe to QCast so you never miss an episode and share it with a colleague. And if you’d like to learn more about how Quanticate supports data-driven solutions in clinical trials, head to our website or get in touch.
Tom
Thanks for tuning in, and we’ll see you in the next episode.
QCast by Quanticate is the podcast for biotech, pharma, and life science leaders looking to deepen their understanding of biometrics and modern drug development. Join co-hosts Tom and Jullia as they explore methodologies, case studies, regulatory shifts, and industry trends shaping the future of clinical research. Where biometric expertise meets data-driven dialogue, QCast delivers practical insights and thought leadership to inform your next breakthrough.
Subscribe to QCast on Apple Podcasts or Spotify to never miss an episode.